The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and Ozempic, could have “an antidepressant effect,” suggesting ...

Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...

Semaglutide reduced the risk of kidney disease worsening ... “This approval for Ozempic allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which ...

Ozempic, the GLP-1 drug initially approved by the U.S. Food and Drug Administration in 2017 to treat Type 2 diabetes, was recently OK’d to help reduce risks linked to chronic kidney disease (CKD).

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...

Now, there's a new benefit to taking Ozempic: It may help manage chronic kidney disease (CKD). On January 28, the U.S. Food and Drug Administration (FDA) approved the GLP-1 drug to reduce the risk ...

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...